Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluation of the Lung Deposition Rate and Distribution Pattern of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease (COPD)

20. juni 2014 opdateret af: Boehringer Ingelheim

γ-Scintigraphic Evaluation of the Lung Deposition Rate and Distribution Pattern of a 99mTc-Labelled Tiotropium Powder Formulation Following Multiple Dose Inhalation of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With COPD

Primary endpoint: whole lung deposition and in-vivo distribution pattern of a 99mTc-labelled tiotropium powder formulation following inhalation via HandiHalerTM in healthy subjects as well as in patients with mild, moderate and severe COPD

Secondary endpoints: pharmacokinetics, pharmacodynamics (effect on lung function), safety and tolerability

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

22

Fase

  • Fase 3

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

40 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • for healthy subjects and COPD patients:

    • Males or females 40 years of age or older.
    • Subjects/Patients must be able to inhale medication from the HandiHalerTM
    • Subjects/Patients must be able to perform all study-related tests including acceptable pulmonary function tests, and must be able to maintain records during the study period as required in the protocol.
    • All subjects/patients must sign an Informed Consent Form prior to participation in the trial in accordance with ICH-GCP and the local legislation, i.e., the COPD patients must give written informed consent prior to pre-study washout of their usual pulmonary medications.
  • for healthy subjects:

    • Normal spirometry as evidenced by a baseline FEV1 ≥ 80 % of predicted normal value for age, height and sex, and FEV1 ≥ 70% of FVC
    • Lifelong non-smokers or ex-smokers with a non-smoking period of at least five years and a maximum of five pack-years.
  • for COPD patients:

    • All patients must have a diagnosis of relatively stable chronic obstructive pulmonary disease and must fulfil the spirometric criteria of the respective sub-group:

      • Mild COPD: 50% ≤ FEV1 < 70% of predicted normal; FEV1/FVC < 70%.
      • Moderate COPD: 35% ≤ FEV1 < 50% of predicted normal; FEV1/FVC < 70%.
      • Severe COPD: FEV1 < 35% of predicted normal; FEV1/FVC < 70%.

Exclusion Criteria:

  • for healthy subjects and COPD patients:

    • Subjects or patients with clinically relevant abnormal baseline haematology, blood chemistry or urinalysis, if the abnormality defines a disease listed as an exclusion criterion will be excluded.
    • All subjects/patients with serum glutamic-oxaloacetic transaminase (SGOT) > 80 IU/L, serum glutamic-pyruvic transaminase (SGPT) > 80 IU/L, bilirubin >2.0 mg/dL or creatinine > 2.0 mg/dL will be excluded regardless of clinical condition. Repeat laboratory evaluation will not be conducted in these subjects/patients.
    • Subjects/Patients with a recent history (i.e., one year or less) of myocardial infarction.
    • Subjects/Patients with any cardiac arrhythmia requiring drug therapy or who have been hospitalised for heart failure within the past three years.
    • Subjects/Patients with known active tuberculosis.
    • Subjects/Patients with a history of cancer within the last five years.
    • Subjects/Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis.
    • Subjects/Patients who have undergone thoracotomy with pulmonary resection.
    • Patients with any upper respiratory infection in the past six weeks prior to the Screening Visit (Visit 1) or during the run-in period
    • Subjects/Patients with known hypersensitivity to anticholinergic drugs, lactose or any other components of the inhalation capsule delivery system
    • Subjects/Patients with known symptomatic prostatic hyperplasia or bladder neck obstruction.
    • Subjects/Patients with known narrow-angle glaucoma.
    • Subjects/Patients with a history of asthma, allergic rhinitis or atopy or who have a total blood eosinophil count ≥ 600 mm3. A repeat eosinophil count will not be conducted in these subjects/patients.
    • Subjects/Patients with a history of and/or active significant alcohol or drug abuse.
    • Subjects/Patients who have taken an investigational drug within one month or six half lives (whichever is shorter) prior to Screening Visit (Visit 1).
  • In addition, for female subjects/patients:

    • Pregnancy.
    • Positive pregnancy test.
    • No adequate contraception, e.g. oral contraceptives, sterilisation, intra uterine device (IUD).
    • Inability to maintain this adequate contraception during the whole study period.
    • Lactation period.
  • for healthy subjects:

    • Subjects with any significant disease will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the subject at risk because of participation in the study or a disease which may influence the results of the study or the subject's ability to participate in the study.
    • Use of any drugs which might influence the results of the trial (within one week prior to administration or during the trial).
  • for COPD patients:

    • Patients with significant diseases other than COPD will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study.
    • COPD patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy.
    • Patients who are currently in a pulmonary rehabilitation programme or who have completed a pulmonary rehabilitation programme in the six week prior to the Screening Visit (Visit 1)
    • Patients who are being treated with oral beta adrenergics or long-acting beta adrenergics such as salmeterol and formoterol.
    • Patients who are being treated with beta blockers.
    • Patients who are being treated with antileukotrienes.
    • Patients who are being treated with cromolyn sodium or nedocromil sodium.
    • Patients who are being treated with antihistamines (H1-receptor antagonists).
    • Patients using oral corticosteroid medication at unstable doses (i.e., less than four weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisolone per day or 20 mg every other day.
    • Patients who are being treated with monoamine oxidase inhibitors or tricyclic antidepressants.
    • Patients with no adequate wash-out period of those medications specified in Section 4.2.2 of the study protocol.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Tiotropium

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Percentage of the total administered radioactivity of 99mTc-labelled tiotropium
Tidsramme: Day 15
Day 15

Sekundære resultatmål

Resultatmål
Tidsramme
Peak plasma concentration at steady state (Cmax,ss)
Tidsramme: Day 14
Day 14
Time to peak plasma concentration at steady state (Tmax,ss)
Tidsramme: Day 14
Day 14
Pre-dose plasma concentration (Cpre)
Tidsramme: Day 1
Day 1
Area under the curve from 0 to 4 hours at steady state (AUCss,0-4h )
Tidsramme: Day 14: 5, 10, 20 min, 1, 2, 4 hours after dosing
Day 14: 5, 10, 20 min, 1, 2, 4 hours after dosing
Renal clearance (CLr)
Tidsramme: Day 14: 0-4 hours and 4-8 hours after drug administration
Day 14: 0-4 hours and 4-8 hours after drug administration
Drug concentration (C20min)
Tidsramme: Day 15: 20 min after drug administration
Day 15: 20 min after drug administration
Drug concentration (C2h)
Tidsramme: Day 15: 2 hours after drug administration
Day 15: 2 hours after drug administration
Change from baseline in forced expiratory volume in the first second (FEV1) in healthy subjects
Tidsramme: Baseline (day -14), day 15 (pre-dose)
Baseline (day -14), day 15 (pre-dose)
Change from baseline in forced Vital Capacity (FVC) in healthy subjects
Tidsramme: Baseline (day -14), day 15 (pre-dose)
Baseline (day -14), day 15 (pre-dose)
Number of adverse events
Tidsramme: up to day 38
up to day 38
Change from baseline in puls rate
Tidsramme: Baseline, day 28
Baseline, day 28
Change from baseline in blood pressure
Tidsramme: Baseline, day 28
Baseline, day 28
Change from baseline in laboratory tests
Tidsramme: Baseline, day 28
Baseline, day 28
Change from baseline in 12 lead electrocardiogram (ECG)
Tidsramme: Baseline, day 28
Baseline, day 28
Change from baseline in physical examination
Tidsramme: Baseline, day 28
Baseline, day 28
Change from baseline in forced expiratory volume in the first second (FEV1) in COPD patients
Tidsramme: Baseline (day -14), pre-dose on day 1, 9, 14 (pre-dose and 0.5, 1, 2, and 3 hours after dosing), 15 and 28
Baseline (day -14), pre-dose on day 1, 9, 14 (pre-dose and 0.5, 1, 2, and 3 hours after dosing), 15 and 28
Change from baseline in forced Vital Capacity (FVC) in COPD patients
Tidsramme: Baseline (day -14), pre-dose on day 1, 9, 14 (pre-dose and 0.5, 1, 2, and 3 hours after dosing), 15 and 28
Baseline (day -14), pre-dose on day 1, 9, 14 (pre-dose and 0.5, 1, 2, and 3 hours after dosing), 15 and 28
Pre-dose plasma concentration in steady state (Cpre,ss)
Tidsramme: day 9, 14, 15
day 9, 14, 15
Area under the curve from 0 to 8 hours at steady state (AUCss,0-8h )
Tidsramme: Day 14: 5, 10, 20 min, 1, 2, 4, 8 hours after dosing
Day 14: 5, 10, 20 min, 1, 2, 4, 8 hours after dosing
Amount excreted into urine from 0 to 4 hours (Aess,0-4h)
Tidsramme: Day 14: 0-4 hours, day 15: 0-4 hours
Day 14: 0-4 hours, day 15: 0-4 hours
Amount excreted into urine from 0 to 8 hours (Aess,0-8h)
Tidsramme: Day 14: 0-8 hours, day 15: 0-8 hours
Day 14: 0-8 hours, day 15: 0-8 hours

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. maj 2002

Primær færdiggørelse (Faktiske)

1. oktober 2002

Datoer for studieregistrering

Først indsendt

20. juni 2014

Først indsendt, der opfyldte QC-kriterier

20. juni 2014

Først opslået (Skøn)

24. juni 2014

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

24. juni 2014

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

20. juni 2014

Sidst verificeret

1. juni 2014

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 205.238

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .